Systemic Inactivation of Alfimeprase Allows for Potentially Fewer Side-Effects

Proposed Doses

(mg/kg)

GLP toxicology

well-tolerated

Estimated Maximum Dose ALF (mg/kg)

0.0

0.2

0.4

0.6

0.8

1.0

1.2

14

1.6

1.8

2.0

2.2

2.4

2.6

2.8

3.0

3.2

3.4

3.6

3.8

4.0

Number of Patients

0

10

20

30

40

50

60

EMD= binding capacity X plasma volume

Clinical doses of alfimeprase do not exceed the binding capacity of alpha-2 macroglobulin

Previous slide

Next slide

Back to first slide

View graphic version